Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411836 | 0.92 | KCNA5 (0.43) | TBXAS1HTTKMT2ACACNA2D1KCNA5 | |
| SCHEMBL5407120 | 0.91 | KMT2A (0.41) | KMT2AADAM17 | |
| SCHEMBL5412150 | 0.86 | TBXAS1 (0.46) | TBXAS1HTR2CCHRNA7HTTKMT2A | |
| SCHEMBL5404063 | 0.86 | KDM4A (0.40) | KMT2A | |
| SCHEMBL5399037 | 0.85 | TRPM8 (0.39) | KMT2A | |
| SCHEMBL5409193 | 0.84 | TSHR (0.43) | KMT2AADAM17 | |
| SCHEMBL5402960 | 0.83 | ALDH1A1 (0.43) | KMT2A | |
| SCHEMBL5416779 | 0.83 | TBXAS1 (0.44) | TBXAS1HTR2CCHRNA7HTTKMT2A | |
| SCHEMBL5404093 | 0.83 | HCRTR1 (0.40) | HTT | |
| SCHEMBL5409148 | 0.83 | TRPV1 (0.48) | TBXAS1HTTKMT2AKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | TBXAS1 802/4885HTR2C 4692/4885CHRNA7 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.